Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.

ABSTRACT:

Objective

To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.

Research design and methods

Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A

SUBMITTER: ORIGIN Trial Investigators 

PROVIDER: S-EPMC3781572 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature